Ionis Pharmaceuticals is opening a Phase 3 safety and efficacy trial of ION363 (jacifusen) in amyotrophic lateral sclerosis (ALS) patients with confirmed mutations in the FUS gene, a known cause of juvenile-onset disease. The trial (NCT04768972) will enroll up to 64 people, ranging in age from 12 to 65,…

Biogen and Ionis Pharmaceuticals have decided to terminate the development of BIIB105, their experimental treatment for amyotrophic lateral sclerosis (ALS), based on data from a Phase 1/2 clinical trial. The therapy resulted in no significant clinical benefit compared with a placebo after six months, and data from…

While neurologists are frustrated with the treatments for amyotrophic lateral sclerosis (ALS) now on the market, they rapidly adopt new therapies that may delay disease progression for use among their patients with the neurodegenerative disorder. That’s according to Spherix Global Insights, a company providing market research and business…